PP_1170x120_10-25-21

IAVI

IAVI and Merck collaborate to develop vaccine against SARS-CoV-2

IAVI and Merck collaborate to develop vaccine against SARS-CoV-2

KENILWORTH, N.J. — Merck  and IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, today announced a new collaboration to develop an investigational vaccine against SARS-CoV-2 to be used for the prevention of COVID-19. This vaccine candidate will use the recombinant vesicular stomatitis virus (rVSV) technology that is the basis

Adheris Health